Paul A. Grayson Sells 86,244 Shares of Skye Bioscience, Inc. Stock
SKYE Stock | USD 4.41 0.13 3.04% |
About 77 percent of Skye Bioscience,'s shareholders are selling. The analysis of the overall investor sentiment regarding Skye Bioscience, Common suggests that quite a large number of traders are terrified. The current market sentiment, together with Skye Bioscience,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Skye Bioscience, Common stock news signals to limit their universe of possible portfolio assets.
Skye |
Skye Bioscience, Inc. Director Paul A. Grayson sold 86,244 shares of the firms stock in a transaction on Monday, November 18th. The stock was sold at an average price of 4.99, for a total value of 430,357.56. Following the transaction, the director now owns 259,701 shares in the company, valued
Read at thelincolnianonline.com
Skye Bioscience, Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Skye Bioscience, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Skye Bioscience, Fundamental Analysis
We analyze Skye Bioscience,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Skye Bioscience, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Skye Bioscience, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Skye Bioscience, is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Skye Bioscience, Common Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Skye Bioscience, stock to make a market-neutral strategy. Peer analysis of Skye Bioscience, could also be used in its relative valuation, which is a method of valuing Skye Bioscience, by comparing valuation metrics with similar companies.
Peers
Skye Bioscience, Related Equities
CADL | Candel Therapeutics | 1.31 |
| ||
CDIO | Cardio Diagnostics | 3.23 |
| ||
UNCY | Unicycive Therapeutics | 4.05 |
| ||
CVKD | Cadrenal Therapeutics, | 7.77 |
| ||
SNTI | Senti Biosciences | 28.60 |
|
Complementary Tools for Skye Stock analysis
When running Skye Bioscience,'s price analysis, check to measure Skye Bioscience,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Skye Bioscience, is operating at the current time. Most of Skye Bioscience,'s value examination focuses on studying past and present price action to predict the probability of Skye Bioscience,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Skye Bioscience,'s price. Additionally, you may evaluate how the addition of Skye Bioscience, to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |